Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention-to-treat analysis with 36 months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group,...

全面介紹

Na minha lista:
書目詳細資料
發表在:Eur J Haematol
Main Authors: Hjorth-Hansen, Henrik, Stenke, Leif, Söderlund, Stina, Dreimane, Arta, Ehrencrona, Hans, Gedde-Dahl, Tobias, Gjertsen, Bjørn Tore, Höglund, Martin, Koskenvesa, Perttu, Lotfi, Kourosh, Majeed, Waleed, Markevärn, Berit, Ohm, Lotta, Olsson-Strömberg, Ulla, Remes, Kari, Suominen, Merja, Simonsson, Bengt, Porkka, Kimmo, Mustjoki, Satu, Richter, Johan
格式: Artigo
語言:Inglês
出版: BlackWell Publishing Ltd 2015
主題:
Original Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365700/
https://ncbi.nlm.nih.gov/pubmed/25082346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.12423
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍